1. 17P Using ex vivo organ culture technology to evaluate a T cell bispecific (TCB) CEACAM5 therapy. (December 2022) Authors: Zundelevich, A.; Ibrahim, B.; Turovsky, L.; Aharon, S.; Bar, V.; Salpeter, S.; Neev, G.; Straussman, R.; Silva, I.; Li, S.; Herter, S.; Bacac, M.; Sadok, S.; Gjorevski, N. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Identification of a unique Staphylococcus aureus ribosomal signature in severe atopic dermatitis. (23rd September 2018) Authors: Brandwein, M.; Fuks, G.; Israel, A.; Nejman, D.; Straussman, R.; Hodak, E.; Harari, M.; Steinberg, D.; Bentwich, Z.; Shental, N.; Meshner, S. Journal: British journal of dermatology Issue: Volume 179:Number 5(2018) Page Start: 1222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Mutant p53 modulates the signal of hepatocyte growth factor (HGF) to endow cancer cells with drug resistance. (July 2016) Authors: Stein, Y.; Jacob, A.; Goldfinger, N.; Straussman, R.; Rotter, V. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗